Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Aamdal

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trialU Jungnelius, U Ringborg, S Aamdal, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.
The Pharmacogenomics Journal|February 17, 2010
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearanceH Edvardsen, P F Brunsvig, H Solvang, et al.
Cancer Chemotherapy and Pharmacology|April 8, 2004
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755A M E Bos, K Boom, A A Vinks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
British Journal of Cancer|December 1, 1996
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groupsH L McLeod, L S Murray, J Wanders, et al.
Clinical and Experimental Immunology|March 2, 2019
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanomaM Nyakas, E Aamdal, K D Jacobsen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumoursA M Bos, E G de Vries, P Dombernovsky, et al.
ESMO Open|September 18, 2022
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatmentE Aamdal, E Skovlund, K D Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trialU Jungnelius, U Ringborg, S Aamdal, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)N Pavlidis, S Aamdal, A Awada, et al.
The Pharmacogenomics Journal|February 17, 2010
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearanceH Edvardsen, P F Brunsvig, H Solvang, et al.
Cancer Chemotherapy and Pharmacology|April 8, 2004
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755A M E Bos, K Boom, A A Vinks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Phase II study of E7070 in patients with metastatic melanomaJ F Smyth, S Aamdal, A Awada, et al.
British Journal of Cancer|December 1, 1996
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groupsH L McLeod, L S Murray, J Wanders, et al.
Clinical and Experimental Immunology|March 2, 2019
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanomaM Nyakas, E Aamdal, K D Jacobsen, et al.
Cancer Chemotherapy and Pharmacology|January 5, 2002
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumoursA M Bos, E G de Vries, P Dombernovsky, et al.
ESMO Open|September 18, 2022
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatmentE Aamdal, E Skovlund, K D Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Pageof 7